00:00Novo Nordisk is introducing multi-month subscription plans for its Wagovi injection and pill,
00:06offering cash-paying patients flat monthly pricing, ranging from $249 to $329 for the injection
00:13and $249 to $289 for the pill, with longer commitments, yielding savings of up to $1,200 annually.
00:22The program, available immediately through telehealth partners, including Roe, Weight Watchers,
00:27and HIMSS and HEARTH, is designed to address the persistent problem of patients abandoning GLP-1 treatment.
00:33A 2025 study estimated roughly 65% of obesity patients stop within a year.
00:40The launch also comes as competitive pressure mounts, with rival Eli Lilly,
00:45which holds an estimated 60% of the branded GLP-1 market, preparing to release its own oral GLP-1
00:51later this year,
00:53making patient retention especially critical for Novo Nordisk.
Comments